Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma

<div>A quantitative method for estimating the likelihood that LUAD patients would develop the illness at 1, 3, and 5 years. (a) A nomogram that estimates the chance of disease-specific survival for LUAD patients at 1, 3, and 5 years. (b) Calibration plots of the nomogram used to assess the overall likelihood of survival at 1, 3, and 5 years.</div>

Mediators of Inflammation

fig6

Figure 6

Figure 6: Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma 